Skip to content

Evaluation of Myocardial Viability : Dual Energy Cardiac CT vs. Cardiac MRI

Evaluation of Myocardial Viability in Late Presentation Myocardial Infarction: Dual Energy Cardiac CT vs. Cardiac MRI.

Status
Terminated
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02360150
Acronym
InfarctusGSI
Enrollment
31
Registered
2015-02-10
Start date
2015-01-10
Completion date
2016-10-07
Last updated
2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myocardial Infarction

Keywords

cardiac angiography, cardiac MRI

Brief summary

The purpose of this study is therefore to show that associated with cardiac angiography echocardiography, in myocardial seen late, would provide the information necessary for the decision revascularization, in a timely manner. This would allow the patient to avoid duplication of tests including risk related to coronary angiography (bleeding complications, stroke ...) and those related to the implantation of coronary stent (stent) without expected earnings in case of non-viability . This would also reduce the length of hospital stay and costs due to numerous reviews.

Detailed description

Percutaneous coronary intervention is not recommended in stable patients with late presentation myocardial infarction, and myocardial viability needs to be evaluated before the procedure. The aim of the study is to evaluate the sensibility and specificity of dual-energy CT for the evaluation of myocardial viability in comparison to cardiac MRI. The experimental procedure is limited to a second CT acquisition performed 10 minutes in dual energy mode. Sensitivity and Specificity of delayed enhancement \>50% of myocardial thickness provided by dual-energy CT will be evaluated in comparison to cardiac MRI.

Interventions

RADIATIONsecond propeller arm scanner

The experimental procedure is to conduct a second helical scanner strictly centered on the heart, 10 minutes after the first helix without inject contrast medium, to assess late enhancement.

Sponsors

University Hospital, Rouen
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Man or woman * Major patient * Patient with electrical, biological and clinical signs of myocardial infarction, with late presentation (\>24 hours) * Creatinine clearance (calculated using the Cockcroft (\<age 65) or MDRD (\> 65 years))formula \> 30 ml / min. * Affiliation to the french social security scheme. * Women of childbearing age: Negative pregnancy test (urine test). * Postmenopausal women, menopause confirmation of diagnosis * Patient able to understand the spoken and written French. * Signature of informed consent

Exclusion criteria

* Collapsus or organ failure requiring urgent care in intensive care unit * Arrhythmia and/or non-reducible tachycardia. * History of allergic reaction after iodinated contrast medium injection. * History of nephrogenic systemic fibrosis. * History of claustrophobia * Unbalanced asthma. * Acute pulmonary edema. * Pregnant or breastfeeding women. * Clinical signs of thyrotoxicosis. * Person placed under judicial protection, * Patient suffering from serious psychiatric disease. * Patients participating in another clinical trial. * Contraindication to MRI

Design outcomes

Primary

MeasureTime frameDescription
Number of patient with a possible evaluation of myocardial viability using dual-energy cardiac CTDay 4To study the sensitivity of dual-energy cardiac CT for the evaluation of myocardial viability, in patients with late presentation myocardial infarction.

Secondary

MeasureTime frameDescription
Number of patient with a possible evaluation of myocardial viability using cardiac MRIDay 4To study the sensitivity of cardiac MRI for the evaluation of myocardial viability in patients with late presentation myocardial infarction.

Countries

France

Contacts

PRINCIPAL_INVESTIGATORBenjamin DUBOURG, Doctor

University Hospital, Rouen

STUDY_DIRECTORJean-Nicolas DACHER, Professor

University Hospital, Rouen

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 15, 2026